24 HIV-specific, ex vivo expanded T cell therapy (HXTC) for HIV clearance: feasibility, safety and efficacy

• Julia M. Sung,
• JoAnnD Kuruc,
• Matthew Clohosey,
• Amanda Crooks,
• Shabnum Patel,
• Lauren Roesch,
• Patrick Hanley,
• CRussell Cruz,
• Nancie Archin,
• JosephJ Eron,
• Nilu Goonetilleke,
• Cliona M. Rooney,
• Catherine M. Bollard,
• David M. Margolis,
• Cynthia L. Gay

Affiliations

Julia M. Sung

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

JoAnnD Kuruc

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Matthew Clohosey

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Amanda Crooks

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Shabnum Patel

Center for Cancer and Immunology Research, Children's National Health System, Washington DC, USA

Lauren Roesch

Center for Cancer and Immunology Research, Children's National Health System, Washington DC, USA

Patrick Hanley

Center for Cancer and Immunology Research, Children's National Health System, Washington DC, USA

CRussell Cruz

Center for Cancer and Immunology Research, Children's National Health System, Washington DC, USA

Nancie Archin

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

JosephJ Eron

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Nilu Goonetilleke

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Cliona M. Rooney

Department of Molecular Virology and Microbiology, Department of Immunology, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA

Catherine M. Bollard

Center for Cancer and Immunology Research, Children's National Health System, Washington DC, USA

David M. Margolis

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA

Cynthia L. Gay

UNC HIV Cure Center, University of North Carolina at Chapel Hill, NC, USA